FREMONT, Calif., Nov. 28 /PRNewswire-FirstCall/ -- Vermillion, Inc. today announced that the United States Patent Office (USPTO) has issued Vermillion U.S. Patent No. 7,297,556 for aiding diagnosis of nephrotic syndrome, a kidney disorder marked by very high or low levels of protein in the urine, which results in bodily swelling and high cholesterol. Nephrotic syndrome is most commonly caused by complications from chronic diabetes or kidney disease. (i)
“The issuance of this patent is another testament to Vermillion’s novel molecular diagnostic technological approach of applying protein biomarkers to aid in the diagnosis and management of serious, life-threatening diseases,” said Gail S. Page, Chief Executive Officer of Vermillion, Inc. “We plan to capitalize on our intellectual property as it grows for the benefit of patients and our shareholders.”
About Vermillion
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has ongoing diagnostic programs in oncology/hematology, cardiology and women’s health with an initial focus in ovarian cancer. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at http://www.vermillion.com.
Forward Looking Statements
This news release contains forward-looking statements that involve significant risks and uncertainties, including the risks and uncertainties discussed in Vermillion’s Form 10-K for the year ended Dec. 31, 2006, and Vermillion’s periodic reports on Form 10-Q and Form 8-K. Vermillion is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise. Forward-looking statement cannot be guaranteed and actual results may differ materially from Vermillion’s current expectations. You are encouraged to read Vermillion’s reports filed with the U.S. Securities and Exchange Commission, available at http://www.sec.gov.
(i) The National Kidney and Urologic Diseases Information Clearinghouse,
a service of the National Institute of Diabetes and Digestive and
Kidney Diseases, National Institutes of Health.
CONTACT: Sue Carruthers of Vermillion, Inc., +1-510-505-2297; or Lori
Murray of WeissComm, Inc., +1-415-946-1070, for Vermillion, Inc.
Web site: http://www.vermillion.com/
